Overview

Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC

Status:
Recruiting
Trial end date:
2024-01-25
Target enrollment:
Participant gender:
Summary
The efficacy of PD-1/PD-L1 combined with chemotherapy in the treatment of extensive small-cell lung cancer is still unsatisfactory. PD-1/PD-L1 combined with chemotherapy and anti-angiogenic drugs may achieve better efficacy.
Phase:
Phase 1
Details
Lead Sponsor:
Zhou Chengzhi
Collaborator:
Jiangsu Hengrui Pharmaceutical Co., Ltd.
Treatments:
Apatinib
Carboplatin
Etoposide